RecruitingAtopic Dermatitis (AD)

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Eligible age

18–75 yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16

Sponsor: Enveda Therapeutics

You may qualify if…

✓ Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit
✓ Have moderate-to-severe AD at screening and baseline as defined by the following criteria:
✓ A vIGA score of 3 (moderate) or 4 (severe)
✓ EASI score of ≥16
✓ BSA ≥10%
✓ PP-NRS score of ≥4
✓ Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months
✓ Use a bland moisturizer at least daily

You may not qualify if…

✕ Current or recurrent medical conditions that could affect the study drug or study assessments
✕ Any illness that could impact participant safety or active infections
✕ Ongoing skin condition or large tattoos that would interfere with clinical assessment
✕ Clinically significant skin infection requiring treatment
✕ Clinically significant abnormal laboratory assessments at screening